Sage Therapeutics (SAGE) down 19% as its Parkinson’s drug fails Phase 2 trials

Visit StreetInsider.com at http://www.streetinsider.com/Hot+List/Sage+Therapeutics+%28SAGE%29+down+19%25+as+its+Parkinson%27s+drug+fails+Phase+2+trials/23079220.html for the full story.